CTI BioPharma Corp. (CTIC)
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price & Analysis

868 Followers

CTIC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.01 - $9.06
Previous Close$9.05
Volume3.07M
Average Volume (3M)5.88M
Market Cap
$1.19B
Enterprise Value$1.18B
Total Cash (Recent Filing)$59.01M
Total Debt (Recent Filing)$48.08M
Price to Earnings (P/E)-15.7
Beta0.19
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding131,880,176
10 Day Avg. Volume3,022,710
30 Day Avg. Volume5,880,400
Standard Deviation0.33
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)-24.82
Price to Sales (P/S)49.49
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.61
Enterprise Value/Gross Profit23.45
Enterprise Value/Ebitda76.21
Forecast
Price Target Upside6.41% Upside
Rating ConsensusHold
Number of Analyst Covering8


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CTIC FAQ

What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest stock price was $4.00 and its highest was $9.05 in the past 12 months.
    What is CTI BioPharma Corp.’s market cap?
    Currently, no data Available
    When is CTI BioPharma Corp.’s upcoming earnings report date?
    CTI BioPharma Corp.’s upcoming earnings report date is Aug 03, 2023 which is in 58 days.
      How were CTI BioPharma Corp.’s earnings last quarter?
      CTI BioPharma Corp. released its earnings results on May 11, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.014.
        Is CTI BioPharma Corp. overvalued?
        According to Wall Street analysts CTI BioPharma Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does CTI BioPharma Corp. pay dividends?
          CTI BioPharma Corp. does not currently pay dividends.
          What is CTI BioPharma Corp.’s EPS estimate?
          CTI BioPharma Corp.’s EPS estimate is -$0.08.
            How many shares outstanding does CTI BioPharma Corp. have?
            CTI BioPharma Corp. has 131,880,170 shares outstanding.
              What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
              CTI BioPharma Corp. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went up 0.224%.
                Which hedge fund is a major shareholder of CTI BioPharma Corp.?
                Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.

                  ---

                  CTI BioPharma Stock Smart Score

                  The CTI BioPharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  CTI BioPharma Corp.

                  CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

                  ---

                  Top 5 ETFs holding CTIC

                  Name
                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  $18.09M
                  8
                  iShares Core S&P Total U.S. Stock Market ETF
                  $839.02K
                  8
                  Fidelity MSCI Health Care Index ETF
                  $485.25K
                  8
                  iShares Russell 3000 ETF
                  $259.61K
                  8
                  Vanguard Russell 3000 ETF
                  $40.17K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold CTIC. The ETFs are listed according to market value of CTIC within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CytomX Therapeutics
                  Molecular Templates
                  Onconova Therapeutics
                  SELLAS Life Sciences Group

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis